Human vWF-A2 Antibody

Catalog #: AF2764
1 Citation Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
AF2764
AF2764-SP

Detection of Human vWF‑A2 by Western Blot.

2 Images

All vWF-A2 Antibodies

Product Details

Citations (1)

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human vWF-A2 Antibody Summary

Species Reactivity

Human

Specificity

Detects human vWF-A2 in direct ELISAs and Western blots.

Source

Polyclonal Sheep IgG

Purification

Antigen Affinity-purified

Immunogen

E. coli-derived recombinant human vWF-A2
Asp1498-Val1665
Accession # NP_000543

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Western Blot

0.5 µg/mL

See below

Simple Western

5 µg/mL

HUVEC human umbilical vein endothelial cells

Immunoprecipitation

25 µg/mL

Conditioned cell culture medium spiked with Recombinant Human vWF-A2 (Catalog # 2764‑WF), see our available Western blot detection antibodies

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Western Blot

View Larger

Detection of Human vWF‑A2 by Western Blot. Western blot shows lysates of HUVEC human umbilical vein endothelial cells. PVDF membrane was probed with 0.5 µg/mL of Sheep Anti-Human vWF-A2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2764) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # HAF016). Specific bands were detected for vWF at approximately 250 kDa and the vWF precursor at 360-460 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

Simple Western

View Larger

Detection of Human vWF‑A2 by Simple Western^TM. Simple Western lane view shows lysates of HUVEC human umbilical vein endothelial cells, loaded at 0.2 mg/mL. A specific band was detected for vWF‑A2 at approximately 250-350 kDa (as indicated) using 5 µg/mL of Sheep Anti-Human vWF‑A2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2764). This experiment was conducted under reducing conditions and using the 66-440 kDa separation system.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Sterile PBS to a final concentration of 0.2 mg/mL.

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: vWF-A2

von Willebrand Factor (vWF) is a large, multimeric glycoprotein made by endothelial cells and megakaryocytes. The pre-pro-vWF protein contains 2813 amino acids (aa), which consists of 22 aa signal peptide, 741 aa propeptide and mature vWF monomer of 2050 aa (1‑4). The pro-vWF undergoes dimerization in the endoplasmic reticulum (ER) through C-terminal “cysteine-knot” (CK) domain. The pro-vWF dimmers are transported to Golgi and form multimers by forming disulfide bond in amino‑terminal region of the mature form. The proteolytic processing of pro-region also occurs in Golgi. The matured vWF is stored in Weibel-Pallade bodies in endothelial cells and granules in megakaryocytes and platelets. The unusually-large vWF (ulvWF) multimers released from cells are very efficient in binding to platelets to form thrombus. The population of these highly active ulvWF multimers is controlled by a specific protease, ADAMTS13, which cleaves between residues Tyr1605 and Met1606 in the A2 domain of vWF. In the plasma, vWF appears as a series of large and intermediate multimers with molecular masses from several thousand to 500 kDa. vWF also performs hemostatic functions (3‑5). In a high shear-stressed environment, vWF undergoes conformational change to expose a binding site for glycoprotein Ib alpha. As a result, vWF facilitates aggregation of platelets. In addition to platelet binding, vWF binds coagulation factor VIII to increase the lifetime of FVIII in plasma. The purified rhvWF-A2 contains the A2 domain of vWF.

References

Sadler, J. E. (1998) Annu. Rev. Biochem. 67:395.
Ruggeri, Z. M. (2003) Cur. Opin. Hemat. 10:142.
Michiels, J. J. et al. (2006) Clin. Appl. Thromb. Hemost. 12:397.
Groot, E. et al. (2007) Cur. Opin. Hemat. 14:284.
Lenting, P. J. et al. (2007) J. Thromb. Haemos. 5:1353.

Long Name

von Willebrand Factor A2 Domain

Entrez Gene IDs

7450 (Human); 22371 (Mouse); 116669 (Rat)

Alternate Names

F8VWF; VWD; VWF von Willebrand factor; vWFA2; vWF-A2

Product Datasheets

Product Datasheet

COA

SDS

Related Research Areas

Citation for Human vWF-A2 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

1 Citation: Showing 1 - 1

Coronary angiogenic effect of long-term administration of Nigella sativa
Authors: LI Al Asoom
BMC Complement Altern Med, 2017-06-13;17(1):308.
Species: Rat
Sample Types: Whole Tissue
Applications: IHC